Trevi Therapeutics, Inc. (TRVI) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Trevi Therapeutics, Inc. (TRVI) Bundle
Whether you’re an investor or analyst, this (TRVI) DCF Calculator is your go-to resource for accurate valuation. Featuring real data from Trevi Therapeutics, Inc., you can adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -26.6 | -32.4 | -32.4 | -29.9 | -33.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .1 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -26.6 | -32.5 | -32.5 | -29.9 | -33.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 57.3 | 45.0 | 36.8 | 12.6 | 83.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .6 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | 1.6 | .9 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.6 | 2.0 | 2.8 | 2.9 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | -.2 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 | 0.10998 |
| EBITAT | -26.6 | -32.5 | -32.5 | -29.9 | -33.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -27.2 | -31.0 | -30.4 | -30.0 | -34.9 | -1.8 | .0 | .0 | .0 | .0 |
| WACC, % | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 | 9.3 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -31 | |||||||||
| Equity Value | 29 | |||||||||
| Diluted Shares Outstanding, MM | 99 | |||||||||
| Equity Value Per Share | 0.30 |
What You Will Get
- Real TRVI Financial Data: Pre-filled with Trevi Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Trevi Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life TRVI Financials: Pre-filled historical and projected data for Trevi Therapeutics, Inc. (TRVI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Trevi’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Trevi’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Access the pre-built Excel file containing Trevi Therapeutics, Inc.'s (TRVI) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Choose This Calculator for Trevi Therapeutics, Inc. (TRVI)?
- Accuracy: Utilizes real Trevi Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily adjust and experiment with various inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Trevi Therapeutics’ valuation before making stock transactions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate forecasts.
- Startup Founders: Understand the valuation processes of established biotech companies like Trevi Therapeutics.
- Consultants: Provide expert valuation assessments for clients in the healthcare sector.
- Students and Educators: Utilize real-life data to learn and teach valuation strategies.
What the Template Contains
- Pre-Filled DCF Model: Trevi Therapeutics, Inc.’s (TRVI) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Trevi’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.